CD5/CD7-Specific CAR-T Cells therapy(Essen Biotech)

N/A

Report date: 2024/06/28 16:56:14

Base Information

Drug NameCD5/CD7-Specific CAR-T Cells therapy(Essen Biotech)
Drug Alias NameCD5/CD7 CAR-T Cells therapy(Essen Biotech)BAH246BAH-246EB-BH2026
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT-cell surface glycoprotein CD5 modulatorsT-cell antigen CD7 modulators
TargetsT-cell surface glycoprotein CD5T-cell antigen CD7
Therapy Area/IndicationsCentral Nervous System DiseasesLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesEssen Biotech
China Registration ClassN/A

Develop Information

Active CompaniesEssen Biotech
Inactive CompaniesN/A
Active IndicationsCentral Nervous System DiseasesLymphoma, T-CellPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A